Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.
- Potential reduction in the dilutive impact of IPO warrants.
- Simplification of capital structure.
- Agreement from holders of 40.7% public and 65.3% private placement warrants to tender their warrants.
- Issuance of up to 3,842,999 new shares may dilute existing shareholders' equity by approximately 6%.
Insights
Zura Bio's decision to commence a warrant exchange offer and consent solicitation is a strategic move aimed at reducing dilution and simplifying its capital structure. For a retail investor, it's important to understand that warrants represent the right to purchase company shares at a predetermined price. This can often result in dilution when they are eventually converted into shares.
By offering to exchange warrants for shares at a ratio of 0.30 Class A ordinary shares per warrant, Zura Bio is effectively looking to mitigate potential dilution. This could make the company's stock more attractive in the long run as it clarifies the total number of shares outstanding. The company has significant backing for this offer with 40.7% of public warrants and 65.3% of private placement warrants already agreeing to tender.
The impact on the market perception can be positive as it simplifies the financial structure, potentially making the stock more appealing to new investors. However, investors should consider the short-term increase in shares outstanding (approximately 6%) which could temporarily affect share price due to the increased supply.
From a financial health perspective, this move can be seen as a proactive step to manage the capital structure effectively. Retail investors should monitor how this simplification plays out in the trading volume and prices of Zura Bio's stock.
This warrant exchange offer by Zura Bio signifies an attempt to create more stability and predictability in its shareholder base. For investors, understanding the ratio offered—0.30 shares per warrant—is important as it shows the company's intention to create a fair trade-off for warrant holders while managing dilution effectively.
It's also notable that the company has engaged with Cantor Fitzgerald as the dealer manager, a reputable firm, which could add credibility to the offer. This could potentially increase confidence among investors about the company's future strategic directions.
Considering industry norms, such moves are not uncommon in biotech and pharmaceutical sectors where capital management is critical due to the high-risk nature of clinical trials and product development. Investors should keep an eye on the company's ability to secure additional consents to reach the required majority for the warrant agreement amendment. If successful, this could further solidify the company’s capital strategy.
This move could be seen as a positive signal for the company's future outlook, as it reduces the complexity of its capital structure, making the stock simpler to evaluate and potentially more appealing to institutional investors.
Exchange Offer and Consent Solicitation Relating to Warrants
The Company is offering to all holders of the IPO warrants the opportunity to receive 0.30 Class A ordinary shares in exchange for each outstanding IPO warrant tendered by the holder and exchanged pursuant to the Offer. Pursuant to the Offer, the Company is offering up to an aggregate of 3,842,999 Class A ordinary shares in exchange for the IPO warrants.
Concurrently with the Offer, the Company is also soliciting consents from holders of the IPO warrants to amend the warrant agreement that governs all of the IPO warrants (the “Warrant Agreement”) to permit the Company to require that each warrant that is outstanding upon the closing of the Offer be exchanged for 0.27 Class A ordinary shares, which is a ratio
The Offer and Consent Solicitation are being made pursuant to a prospectus/offer to exchange, dated July 11, 2024 (the “Prospectus/Offer to Exchange”), and Schedule TO, dated July 12, 2024 (the “Schedule TO”), each of which has been filed with the
The Company’s Class A ordinary shares and public warrants are listed on The Nasdaq Capital Market under the symbols “ZURA” and “ZURAW,” respectively. As of July 10, 2024, there were (i) 63,746,453 Class A ordinary shares outstanding, and (ii) a total of 12,809,996 IPO warrants were outstanding, including our public warrants and private placement warrants. Assuming all IPO warrant holders tender their IPO warrants for exchange in the Offer, the Company would expect to issue up to 3,842,999 Class A ordinary shares, resulting in 67,589,452 Class A ordinary shares outstanding (an increase of approximately
The Company has engaged Cantor Fitzgerald & Co. as the dealer manager for the Offer and Consent Solicitation (the “Dealer Manager”). Any questions or requests for assistance concerning the Offer and Consent Solicitation may be directed to the Dealer Manager at (212) 915-1800 (toll-free).
Alliance Advisors has been appointed as the information agent for the Offer and Consent Solicitation (the “Information Agent”), and Continental Stock Transfer & Trust Company has been appointed as the exchange agent (the “Exchange Agent”). Any questions or requests for assistance concerning the Offer and Consent Solicitation may be directed to the Information Agent at:
Alliance Advisors, LLC
200 Broadacres Drive, 3rd Floor
Call Toll Free: 1-844-717-2302
Email: zura@allianceadvisors.com
Important Additional Information Has Been Filed with the SEC
Copies of the Schedule TO and Prospectus/Offer to Exchange will be available free of charge at the website of the SEC at www.sec.gov. Requests for documents may also be directed to the Information Agent at 1-844-717-2302 or via the following email address: zura@allianceadvisors.com. A registration statement on Form S-4 relating to the securities to be issued in the Offer has been filed with the SEC but has not yet become effective. Such securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This announcement is for informational purposes only and shall not constitute an offer to purchase or a solicitation of an offer to sell the IPO warrants or an offer to sell or a solicitation of an offer to buy any Class A ordinary shares in any state in which such offer, solicitation, or sale would be unlawful before registration or qualification under the laws of any such state. The Offer and Consent Solicitation are being made only through the Schedule TO and Prospectus/Offer to Exchange, and the complete terms and conditions of the Offer and Consent Solicitation are set forth in the Schedule TO and Prospectus/Offer to Exchange.
Holders of the IPO warrants are urged to read the Schedule TO and Prospectus/Offer to Exchange carefully before making any decision with respect to the Offer and Consent Solicitation because they contain important information, including the various terms of, and conditions to, the Offer and Consent Solicitation.
None of the Company, any of its management or its board of directors, or the Information Agent, the Exchange Agent, or the Dealer Manager makes any recommendation as to whether or not holders of IPO warrants should tender IPO warrants for exchange in the Offer or consent to the Warrant Amendment in the Consent Solicitation.
About Zura Bio
Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing of the Offer and Consent Solicitation. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, but not limited to those described under the section entitled “Risk Factors” in the Company’s Registration Statement on Form S-4, filed with the SEC on July 11, 2024, as such factors may be updated from time to time in the Company’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.
New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. We do not give any assurance that we will achieve our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711755301/en/
Megan K. Weinshank
Head of Investor Relations
ir@zurabio.com
Source: Zura Bio Limited
FAQ
What is Zura Bio's recent announcement about?
What does the exchange offer entail for Zura Bio's IPO warrants?
What is the deadline for Zura Bio's exchange offer?
How many new shares could Zura Bio issue from the exchange offer?
What percentage of Zura Bio's warrant holders have agreed to the exchange offer?
What is the potential impact on Zura Bio's outstanding shares if the exchange offer is fully accepted?
